A specific synbiotic-containing amino acid-based formula restores gut microbiota in non-IgE mediated cow’s milk allergic infants: a randomized controlled trial

Clinical and Translational Allergy
• Research
• Open Access

• Harm WopereisView ORCID ID profile,
• Marleen T. J. van Ampting,
• Aysun Cetinyurek-Yavuz,
• Rob Slump,
• David C. A. Candy,
• Assad M. Butt,
• Diego G. Peroni,
• Yvan Vandenplas,
• Adam T. Fox,
• Neil Shah,
• Guus Roeselers,
• Lucien F. Harthoorn,
• Louise J. Michaelis,
• Jan KnolEmail author,
• Christina E. West and
• the ASSIGN study group

Clinical and Translational Allergy20199:27

https://doi.org/10.1186/s13601-019-0267-6

Abstract

Background

Altered gut microbiota is implicated in cow’s milk allergy (CMA) and differs markedly from healthy, breastfed infants. Infants who suffer from severe CMA often rely on cow’s milk protein avoidance and, when breastfeeding is not possible, on specialised infant formulas such as amino-acid based formulas (AAF). Herein, we report the effects of an AAF including specific synbiotics on oral and gastrointestinal microbiota of infants with non-IgE mediated CMA with reference to healthy, breastfed infants.

Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials

Respiratory Research
•  Research
• Open Access

• Xiao-feng Xiong,
• Min Zhu,
• Hong-xia Wu,
• Li-li Fan and
• De-yun ChengEmail author

Respiratory Research201920:108

https://doi.org/10.1186/s12931-019-1065-3

Abstract

Background

Several recent clinical trials have assessed the effects of dupilumab in uncontrolled asthma, but reached no definite conclusion. We therefore conducted this meta-analysis to evaluate the overall efficacy and safety of dupilumab for the treatment of uncontrolled asthma.

Read the latest research in Allergy and Immunology

Dear DR

We want to alert you to a selection of featured journals from our open access Allergy and Immunology portfolio. Choose the journal that fits your research and stay up to date with the latest research - browse our portfolio below!

Identification of immunodominant IgE binding epitopes of Der p 24, a major allergen of Dermatophagoides pteronyssinus

Clinical and Translational Allergy

• Ze-Lang Cai†,
• Jia-Jie Chen†,
• Zhen Zhang,
• Yi-Bo Hou,
• Yong-shen He,
• Jin-Lyu SunEmail author and
• Kunmei JiEmail authorView ORCID ID profile

†Contributed equally

Clinical and Translational Allergy20199:28

Abstract

Background

The identification of house dust mite (HDM) allergens and epitopes is important for allergy diagnosis and treatment. We sought to identify the Dermatophagoides pteronyssinus group 24 allergen (Der p 24) and to identify its immunodominant IgE epitope(s).

Immunosuppressive therapy with rituximab in common variable immunodeficiency

• Open Access

• Antonio Pecoraro,
• Ludovica Crescenzi,
• Maria Rosaria Galdiero,
• Giancarlo Marone,
• Felice Rivellese,
• Francesca Wanda Rossi,
• Amato de Paulis,
• Arturo Genovese and
• Giuseppe SpadaroEmail authorView ORCID ID profile

Clinical and Molecular Allergy201917:9

Abstract

Common variable immunodeficiency (CVID) is the most frequent symptomatic primary antibody deficiency in adulthood and is characterized by the marked reduction of IgG and IgA serum levels. Thanks to the successful use of polyvalent immunoglobulin replacement therapy to treat and prevent recurrent infections, non-infectious complications, including autoimmunity, polyclonal lymphoproliferation and malignancies, have progressively become the major cause of morbidity and mortality in CVID patients. The management of these complications is particularly challenging, often requiring multiple lines of immunosuppressive treatments. Over the last 5–10 years, the anti-CD20 monoclonal antibody (i.e., rituximab) has been increasingly used for the treatment of both autoimmune and non-malignant lymphoproliferative manifestations associated with CVID.

Topical application of nebulized human IgG, IgA and IgAM in the lungs of rats and non-human primates

Respiratory Research  
• Research
• Open Access

• Cédric VonarburgEmail authorView ORCID ID profile,
• Marius Loetscher,
• Martin O. Spycher,
• Alain Kropf,
• Marlies Illi,
• Sharon Salmon,
• Sean Roberts,
• Karin Steinfuehrer,
• Ian Campbell,
• Sandra Koernig,
• Joseph Bain,
• Monika Edler,
• Ulrich Baumann,
• Sylvia Miescher,
• Dennis W. Metzger,
• Alexander Schaub,
• Fabian Käsermann and
• Adrian W. Zuercher

Respiratory Research201920:99

https://doi.org/10.1186/s12931-019-1057-3

Abstract

Background

Recurrent and persistent infections are known to affect airways of patients with Primary Immunodeficiency despite appropriate replacement immunoglobulin serum levels. Interestingly, patients with Chronic Obstructive Pulmonary Disease or with non-CF bronchiectasis also show similar susceptibility to such infections. This may be due to the limited availability of immunoglobulins from the systemic circulation in the conductive airways, resulting in local immunodeficiency. Topical application of nebulized plasma-derived immunoglobulins may represent a means to address this deficiency. In this study, we assessed the feasibility of nebulizing plasma-derived immunoglobulins and delivering them into the airways of rats and non-human primates.

Stella Lee, MD: CRSwNP Patients, Before Dupilumab

Source: 

Conjunctivitis in dupilumab clinical trials

Clinical Trial 

 

Open Access

B. Akinlade 

 

E. Guttman‐Yassky 

 

M. de Bruin‐Weller 

 

E.L. Simpson 

 

A. Blauvelt 

 

M.J. Cork 

 

E. Prens 

 

P. Asbell 

 

E. Akpek 

 

J. Corren 

 

C. Bachert 

 

I. Hirano 

 

J. Weyne 

 

A. Korotzer 

 

Z. Chen 

… See all authors 

 

https://doi.org/10.1111/bjd.17869

Summary

Background

Dupilumab blocks the shared receptor component for interleukin (IL)‐4 and IL‐13. It is approved in the U.S.A. for patients aged ≥ 12 years with moderate‐to‐severe atopic dermatitis (AD) uncontrolled by topical prescription medicines or who cannot use topical medicines, for patients in Japan whose AD is uncontrolled with existing therapies, for patients with moderate‐to‐severe AD in Europe who are candidates for systemic therapy and for patients aged ≥ 12 years for maintenance treatment of moderate‐to‐severe asthma uncontrolled with their current medicines. AD trials have reported increased incidence of conjunctivitis for dupilumab vs. placebo.